The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 20, 2022
Filed:
Nov. 22, 2016
Applicant:
Trustees of Boston University, Boston, MA (US);
Inventors:
Wilson W. Wong, Brookline, MA (US);
Jang Hwan Cho, Chestnut Hill, MA (US);
Assignee:
TRUSTEES OF BOSTON UNIVERSITY, Boston, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 14/725 (2006.01); C07K 16/32 (2006.01); C07K 16/28 (2006.01); C07K 14/47 (2006.01); A61K 39/00 (2006.01); C07K 16/18 (2006.01); C07K 16/30 (2006.01); C12N 9/90 (2006.01); C07K 16/00 (2006.01); C07K 14/315 (2006.01); C07K 14/705 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); A61K 39/0011 (2013.01); C07K 14/315 (2013.01); C07K 14/4738 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/00 (2013.01); C07K 16/18 (2013.01); C07K 16/28 (2013.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); C12N 9/90 (2013.01); A61K 2039/5156 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/70 (2013.01); C07K 2319/73 (2013.01); C07K 2319/80 (2013.01); C07K 2319/81 (2013.01);
Abstract
Described herein is a chimeric antigen receptor (CAR) platform with the ability to (a) serve as an ON/OFF switch (with the ability for tenability/titrability), (b) sense multiple antigens and perform logic computations, and/or (c) independently regulate multiple signaling pathways. The compositions provided herein permit the degree of control and discrimination necessary to optimize CAR T cell therapy. Also described herein are cells comprising such compositions and the use of these compositions and/or cells in the treatment of cancer.